Analyst Ratings For Genocea Biosciences (NASDAQ:GNCA)
Today, HC Wainwright initiated coverage on Genocea Biosciences (NASDAQ:GNCA) with a Buy with a price target of $5.00.
Some recent analyst ratings include
- 3/8/2018-HC Wainwright initiated coverage with a Buy rating.
- 3/5/2018-Cantor Fitzgerald initiated coverage with a Overweight rating.
- 2/12/2018-Robert W. Baird initiated coverage with a Outperform rating.
- 2/6/2018-Needham & Company LLC Upgrade from a “Hold ” rating to a ” Buy” rating.
- 11/2/2017-Piper Jaffray Companies Reiterated Rating of Overweight.
- 9/26/2017-Cowen Reiterated Rating of Buy.
- 9/25/2017-Stifel Nicolaus was Downgraded by analysts at Stifel Nicolaus from a “Buy ” rating to a ” Hold” rating. They now have a $2.50 price target on the stock, up previously from $15.00 .
Recent Insider Trading Activity For Genocea Biosciences (NASDAQ:GNCA)
Genocea Biosciences (NASDAQ:GNCA) has insider ownership of 6.70% and institutional ownership of 10.29%.
- On 1/17/2018 William D Clark, CEO, bought 25,000 with an average share price of $0.80 per share and the total transaction amounting to $20,000.00.
- On 7/24/2017 Jonathan Poole, CFO, sold 45,000 with an average share price of $6.00 per share and the total transaction amounting to $270,000.00.
- On 11/8/2016 Eric S. Hoffman, Insider, bought 7,000 with an average share price of $3.49 per share and the total transaction amounting to $24,430.00.
- On 11/7/2016 Jonathan Poole, CFO, bought 7,000 with an average share price of $3.34 per share and the total transaction amounting to $23,380.00.
- On 11/7/2016 William D. Clark, Insider, bought 2,800 with an average share price of $3.49 per share and the total transaction amounting to $9,772.00.
- On 5/9/2016 Jonathan Poole, CFO, bought 4,000 with an average share price of $3.88 per share and the total transaction amounting to $15,520.00.
- On 12/16/2015 William D Clark, CEO, bought 3,800 with an average share price of $6.45 per share and the total transaction amounting to $24,510.00.
Recent Trading Activity for Genocea Biosciences (NASDAQ:GNCA)
Shares of Genocea Biosciences closed the previous trading session at 1.18 up +0.07 6.36% with shares trading hands.